

PRESS RELEASE
5 June 2012



BioInvent and ThromboGenics to Regain Full Rights to TB-403

Plan to evaluate the potential of this therapeutic antibody against PIGF in cancer and non-cancer indications, including ophthalmology

Lund, Sweden and Leuven, Belgium – 5 June 2012 – BioInvent International AB (OMXS: BINV) and co-development partner ThromboGenics NV (Euronext Brussels: THR) announce today that they will regain global rights to TB-403 from Roche (SIX: RO, ROG; OTCQX: RHHBY). TB-403 was licensed to Roche in 2008. ThromboGenics and BioInvent plan to further evaluate the potential of TB-403 in certain cancer and non-cancer indications, including ophthalmology. Clinical studies with TB-403 to-date have shown that it is safe and well tolerated. Roche's decision was due to the prioritization of resources in the Roche portfolio.

TB-403 is a monoclonal antibody against placental growth factor (PIGF). PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels. TB-403's ability to block the growth of new blood vessels and modulate inflammation means it could potentially be used in a broad range of cancer and non-cancer indications.

Svein Mathisen, CEO of BioInvent, said: "TB-403's ability to selectively block the formation of new blood vessels provides us with a therapeutic antibody candidate that could have potential in indications where it has so far not been fully assessed. We intend to evaluate such opportunities and will provide an update when data are available."

Dr Patrik De Haes, CEO of ThromboGenics, added: "Regaining all rights to TB-403, an antibody which blocks PIGF, will allow us to evaluate its potential as a treatment for a number of significant retinal diseases including diabetic retinopathy and AMD. We believe that our lead product ocriplasmin will allow us to establish a strong market position in the treatment of retinal disorders where vitreomacular adhesion plays a role. By investing in the development of TB-403 we could have another exciting new product to accelerate the growth of our emerging ophthalmology franchise."

- END -

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focusing on developing antibody drugs. The Company currently has four clinical development projects within the areas of thrombosis, cancer and atherosclerosis. The Company has signed various strategic alliances to strengthen the product pipeline and

increase the likelihood of success. These partners include Genentech, Human Genome Sciences and ThromboGenics.

The company's competitive position is underpinned by its proprietary antibody development platform. The scope and strength of this platform is also utilized by partners, such as Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe, UCB and XOMA. More information is available at www.bioinvent.com.

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company's lead product, ocriplasmin, has successfully completed two Phase III clinical trials for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA)/ Vitreomacular Traction (VMT). The MAA for ocriplasmin has been accepted for review in Europe and the BLA has been re-submitted in the U.S. Ocriplasmin is in Phase II clinical development for additional vitreoretinal conditions.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments, plus an attractive level of royalties on Alcon's net sales of ocriplasmin. ThromboGenics and Alcon intend to share the costs equally of developing ocriplasmin for a number of new vitreoretinal indications.

ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

For further information, please contact:

BioInvent International AB

Svein Mathisen
President & CEO
Mobile: +46 (0)708 97 82 13
E-mail: svein.mathisen@bioinvent.com

Sten Westerberg
Vice President, Investor Relations
Mobile: +46 (0)768 68 50 09
E-mail: sten.westerberg@bioinvent.com

College Hill (media enquiries)
Melanie Toyne Sewell
Phone: +44 (0)20 7866 7856
Rebecca Skye Dietrich
Tel: +1 (857) 241 0795
E-mail: bioinvent@collegehill.com

The Trout Group
Christine Yang
Vice President
Tel: +1 646 378 2929
E-mail: cyang@troutgroup.com

ThromboGenics NV

Dr Patrik De Haes
CEO
Tel: +32 16 75 13 10
E-mail: patrik.dehaes@thrombogenics.com

Chris Buyse
CFO
Tel: +32 16 75 13 10
E-mail: chris.buyse@thrombogenics.com

Citigate Dewe Rogerson
David Dible / Nina Enegren / Sita Shah
Tel: +44 20 7638 9571
E-mail: sita.shah@citigatedr.co.uk

The Trout Group
Todd James, Director
Simon Harnest, Associate
Tel: +1 646 378 2929
E-mail: tjames@troutgroup.com

BioInvent International AB (publ)

Co. reg. No. 556537-7263,
Visiting address: Sölvegatan 41
Mailing address: SE-223 70 LUND
Phone: +46 (0)46 286 85 50

ThromboGenics NV

Gaston Geenslaan 1
B-3001 Heverlee
Belgium
Phone: +32 (0)16 75 13 10

Legal disclaimer

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 7.30 a.m. CET, on 5 June, 2012.